Cell line · CVCL_1270
Papers69
1 to 20 of 69
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HLA class I-specific nucleolin peptides induce therapeutic T cells in triple-negative breast cancer patients. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mapping the Subtype-Specific PARP1 ADP-Ribosylated Proteome in Breast Cancer Cells. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PFDN5 synergizes with anti-PD1 therapy to promote triple-negative breast cancer cell death through JAK2/STAT3/c-Myc signaling axis. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cyclin E modulates vulnerability to CDC7 kinase inhibition. | Oncogenesis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of novel circular RNAs of the apoptosis-related BAX gene in breast cancer, by combining nanopore and next-generation sequencing. | Mol Genet Genomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Comparative theranostic efficacy of 177Lu- and 161Tb-labeled A1K2 SdAb in mesothelin-positive tumors. | Eur J Nucl Med Mol Imaging | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer. | Cancer Metab | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 40654790 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| EYA3 regulation of NF-κB and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. | Front Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1270/papers